Investigational Lupus Drug Blisibimod Gets Go-ahead for Phase 3 Development

The U.S. Food and Drug and the European Medicines Agency gave permission to Anthera Pharmaceuticals to submit a design for a Phase 3 trial to test the experimental drug blisibimod among patients with lupus. The FDA describes Phase 3 trial as: In Phase III trials, the experimental study drug or treatment is given to large groups of people (1,000-3,000) to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the experimental drug or treatment to be used safely.